China's foreign minister pushes for dialogue to resolve Middle East conflict Reuters
Why INCR Stock dropped -3.64% Today — RQD Quant Desk Flash
Intercure Ltd. (INCR) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is INCR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Intercure Ltd. (NASDAQ: INCR) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $3.97 (-3.64% 1D, market cap $61.8M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, INCR ranks #328 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does INCR compare to RNTX and APLM in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), INCR carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, RNTX (Rein Therapeutics Inc.) holds a D grade (49/100 RQD, P/E N/A, ROIC -35.0%, cap $62.7M) and APLM (Apollomics Inc. (Class A)) posts a C grade (62/100 RQD, P/E N/A, ROIC —, cap $60.2M). Among the 5-stock peer group, SPRO leads on earnings multiple (7.5x) while SPRO leads on capital efficiency (26.6% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for INCR?
▼
For Intercure Ltd. (INCR), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #328 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL Trailing 12 Months: 0% FCF Margin ($1.7M FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
⚔️ Adversarial Opposing Case: What Could Spark a INCR Turnaround Squeeze
While INCR currently carries a cautious 48/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.09) and Max Pain ($4.17) forces dealer call-delta covering toward $7.93.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Why INCR Stock dropped -3.64% Today — RQD Quant Desk Flash
Intercure Ltd. (INCR) dropped -3.64% to $3.97, trading at 14% of its 52-week range ($3.4 – $7.55). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 14% of its 52-week range ($3.4 – $7.55) with RSI-14 at 28.7 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±9.2% around $3.97 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $1.7M annual free cash flow.
COMMENTARY: Asia's crude oil imports back to pre-war levels but refined fuels lag Reuters
US voters in a sour economic mood heading into midterm elections Reuters
Iranians have left Doha talks, draft proposal for US deal being circulated, official says Reuters
Saudi civil defence sounds all-clear after alerts in southern cities Reuters
World's energy supply buffers have been eroded, ADNOC CEO says Reuters
Gold rebounds from one-year low as oil slides ahead of US midterms Reuters
China's Xi says Middle East should not become battleground for great power rivalry Reuters
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INCR)
- ✓Walkthrough of INCR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
INCR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on INCR today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for INCR. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INCR)
1. Head-to-Head Health Care Peer Comparison (INCR vs. RNTX, APLM, XBIT, SPRO)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Intercure Ltd. (INCR) ranks #328 by composite RQD confidence (48/100, grade D) and #723 by equity capitalization ($61.8M). Within this direct 5-issuer industry benchmark cohort, SPRO leads on earnings valuation at 7.5x trailing P/E, while SPRO leads on capital efficiency and profitability with 26.6% ROIC and — gross margin. APLM currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with INCR at 48/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| INCR
ACTIVE
Intercure Ltd. | D | 48/100 | — | — | — | -3.64% | $61.8M | Benchmark Subject |
| RNTX Rein Therapeutics Inc. | D | 49/100 | — | — | -35.0% | -7.79% | $62.7M | /rntx-vs-incr → |
| APLM Apollomics Inc. (Class A) | C | 62/100 | — | — | — | -0.53% | $60.2M | /aplm-vs-incr → |
| XBIT XBiotech Inc. | D- | 37/100 | — | — | -35.0% | -3.09% | $59.1M | /xbit-vs-incr → |
| SPRO Spero Therapeutics Inc. | D- | 43/100 | 7.5x | — | 26.6% | -4.50% | $64.6M | /spro-vs-incr → |
2. INCR Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTIntercure Ltd. (INCR) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $61.8M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. INCR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs INCR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Intercure Ltd. (NASDAQ: INCR) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $3.97 (-3.64% 1D, market cap $61.8M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, INCR ranks #328 in composite RQD confidence.
How does INCR compare to RNTX and APLM in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), INCR carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, RNTX (Rein Therapeutics Inc.) holds a D grade (49/100 RQD, P/E N/A, ROIC -35.0%, cap $62.7M) and APLM (Apollomics Inc. (Class A)) posts a C grade (62/100 RQD, P/E N/A, ROIC —, cap $60.2M). Among the 5-stock peer group, SPRO leads on earnings multiple (7.5x) while SPRO leads on capital efficiency (26.6% ROIC).
What are the biggest fundamental strengths and SEC risk factors for INCR?
For Intercure Ltd. (INCR), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #328 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is INCR trading relative to its 50-day, 200-day, and 52-week technical levels?
INCR last traded at $3.97 (-3.64% on volume of 14,680 shares), positioning the stock -22.00% below its 50-day simple moving average ($5.09) and -14.07% below its 200-day simple moving average ($4.62). Across its 52-week range of $3.40 to $7.55, INCR sits at the 13.7% percentile with a 14-day RSI of 28.7 (OVERSOLD (<32)) and an implied next-earnings move of ±9.2% ($3.60 to $4.34).
INCR Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is INCR stock moving today?
Why INCR Stock dropped -3.64% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.